Analysts See $-0.72 EPS for Gemphire Therapeutics Inc. (GEMP)

March 16, 2018 - By Vivian Park

 Analysts See $ 0.72 EPS for Gemphire Therapeutics Inc. (GEMP)

Analysts expect Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report $-0.72 EPS on March, 21.They anticipate $0.06 EPS change or 7.69 % from last quarter’s $-0.78 EPS. After having $-0.82 EPS previously, Gemphire Therapeutics Inc.’s analysts see -12.20 % EPS growth. The stock decreased 2.35% or $0.17 during the last trading session, reaching $7.06. About 102,792 shares traded. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has 0.00% since March 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Ratings Coverage

Among 3 analysts covering Gemphire Therapeutics (NASDAQ:GEMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Gemphire Therapeutics has $25 highest and $15 lowest target. $19’s average target is 169.12% above currents $7.06 stock price. Gemphire Therapeutics had 3 analyst reports since August 30, 2016 according to SRatingsIntel. The stock of Gemphire Therapeutics Inc. (NASDAQ:GEMP) earned “Buy” rating by Canaccord Genuity on Tuesday, August 30. The company was initiated on Tuesday, August 30 by RBC Capital Markets. The rating was initiated by Jefferies with “Buy” on Tuesday, August 30.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $97.26 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.